-
Alcohol-associated liver disease and public health policies Hepatology (IF 12.9) Pub Date : 2024-07-01 Shreya Sengupta, Victoria Gill, Jessica L. Mellinger
Alcohol-associated liver disease (ALD) rates have increased substantially in the United States (US) and elsewhere around the globe. These increases are largely the result of increases in alcohol use. While there are many levels at which alcohol use interventions can be implemented in order to reduce alcohol use and its negative health consequences, public policy initiatives have emerged as a powerful
-
To recover or not to recover from ACLF: Ask the monocytes Hepatology (IF 12.9) Pub Date : 2024-07-01 Amin M. Amin, Jacqueline G. O’Leary
-
A novel phosphodiesterase inhibitor for the treatment of chronic liver injury and metabolic diseases Hepatology (IF 12.9) Pub Date : 2024-07-01 Dalton W. Staller, Sanjali S. Panigrahi, Yahani P. Jayasinghe, Yuxiang Dong, Sohan Mahto, Virender Kumar, Donald R. Ronning, Ram I. Mahato
Background and Aims: Chronic liver disease (CLD) leads to approximately two million deaths annually. Cyclic adenosine monophosphate (cAMP) signaling has long been studied in liver injury, particularly in the regulation of fatty acid (FA) β-oxidation and pro-inflammatory polarization of tissue-resident lymphocytes. Phosphodiesterase 4B (PDE4B) inhibition has been explored as a therapeutic modality,
-
Is curcumin the new kid on the block for the treatment of MASH? Hepatology (IF 12.9) Pub Date : 2024-06-28 Shira Zelber-Sagi, Jörn M. Schattenberg
-
Reversal of lipid metabolism as a therapeutic approach for hepatocellular carcinoma Hepatology (IF 12.9) Pub Date : 2024-06-27 Daming Gao, Judy Wai Ping Yam
-
Letter to the Editor: Refining retrieval and chunking strategies for enhanced clinical reliability of large language models in liver disease Hepatology (IF 12.9) Pub Date : 2024-06-27 Mauro Giuffrè
-
Reply: Refining retrieval and chunking strategies for enhanced clinical reliability of large language models in liver disease Hepatology (IF 12.9) Pub Date : 2024-06-27 Jin Ge, Steve Sun, Joseph Owens, Victor Galvez, Oksana Gologorskaya, Jennifer C. Lai, Mark J. Pletcher, Ki Lai
-
Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder Hepatology (IF 12.9) Pub Date : 2024-06-27 Lamia Y. Haque, Lorenzo Leggio
The public health impact of alcohol-associated liver disease (ALD), a serious consequence of problematic alcohol use, and alcohol use disorder (AUD) is growing, with ALD becoming a major cause of alcohol-related death overall and the leading indication for liver transplantation in the United States. Comprehensive care for ALD often requires treatment of AUD. Although there is a growing body of evidence
-
Bridging the gap: A new tool to down select HCV vaccine candidates Hepatology (IF 12.9) Pub Date : 2024-06-27 John Lokman Law, Heidi E. Drummer
-
Alcohol-Associated liver disease: Emerging therapeutic strategies Hepatology (IF 12.9) Pub Date : 2024-06-26 Benjamin H. Mullish, Mark R. Thursz
The large and growing burden of alcohol-related liver disease (ALD) – and the considerable burden of morbidity and mortality associated with it – has been a drive towards ongoing research into novel strategies for its treatment, with a particular focus upon alcohol-related hepatitis (AH). Management of alcohol-use disorder (AUD) forms the central pillar of ALD care, with evidence-based psychological
-
Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients Hepatology (IF 12.9) Pub Date : 2024-06-26 Xingmei Liao, Rong Fan
-
Therapeutic manipulation of the microbiome in liver disease Hepatology (IF 12.9) Pub Date : 2024-06-26 Gopanandan Parthasarathy, Harmeet Malhi, Jasmohan S. Bajaj
Myriad associations between the microbiome and various facets of liver physiology and pathology have been described in the literature. Building on descriptive and correlative sequencing studies, metagenomic studies are expanding our collective understanding of the functional and mechanistic role of the microbiome as mediators of the gut-liver axis. Based on these mechanisms, the functional activity
-
‘Regarding Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography’ Hepatology (IF 12.9) Pub Date : 2024-06-26 Madhumita Premkumar, Anand Kulkarni, Manhal Izzy
-
Aramchol improves hepatic fibrosis in MASH: Results of multimodality assessment using both conventional and digital pathology Hepatology (IF 12.9) Pub Date : 2024-06-25 Vlad Ratziu, Yusuf Yilmaz, Don Lazas, Scott L. Friedman, Caroline Lackner, Cynthia Behling, Oscar W. Cummings, Li Chen, Matthieu Petitjean, Yossi Gilgun-Sherki, Tali Gorfine, Shaul Kadosh, Eli Eyal, Arun J. Sanyal
Background and Aims: Antifibrotic trials rely on conventional pathology (CP) despite recognized limitations. We compared single fiber digital image analysis (DIA) with CP to quantify the antifibrotic effect of Aramchol, a stearoyl-CoA desaturase 1 inhibitor in development for metabolic-dysfunction associated steatohepatitis (MASH). Approach and Results: 51 MASH patients enrolled in the open-label part
-
Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury Hepatology (IF 12.9) Pub Date : 2024-06-25 Xin Luo, Jixian Yu
-
Letter to the Editor: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis Hepatology (IF 12.9) Pub Date : 2024-06-24 Kai Kang, Yijun Wu
-
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study Hepatology (IF 12.9) Pub Date : 2024-06-24 Meng Zhu, Mengqi Qu, Shengxia Lv, Fuzhen Pan, Yongsheng Zhang
-
Letter to the Editor: Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline Hepatology (IF 12.9) Pub Date : 2024-06-24 Fei Zhang, Jiahe Wang
-
Modulation of monocyte activity by hepatocellular MicroRNA delivery via hepatitis B virus surface antigen particles: Implications for pathobiology of chronic hepatitis B Hepatology (IF 12.9) Pub Date : 2024-06-21 Jin Li, Xiao Ma, Qinkao Xuan, Qiang Li, Min Wu, Bisheng Shi, Zhong Fang, Liang Chen, Jieliang Chen, Yumei Wen, Chuanwu Zhu, Li Zhu, Xiaonan Zhang, Zhenghong Yuan
Background and Aims: The surface antigen of hepatitis B virus (HBsAg) serves as an important immune-modulatory factor in chronic hepatitis B (CHB). One aspect of such modulation may act through monocytes which are the major antigen presenting cells (APCs) taking up HBsAg. There is evidence for the encapsulation of hepatocellular miRNAs by HBsAg particles, while its pathobiological significance is unclear
-
Utility of methylated DNA markers for the diagnosis of malignant biliary strictures Hepatology (IF 12.9) Pub Date : 2024-06-21 Matthew A. Cooley, Amber R. Schneider, Emily G. Barr Fritcher, Dragana Milosevic, Michael J. Levy, Amber R. Bridgeman, John A. Martin, Bret T. Petersen, Barham K. Abu Dayyeh, Andrew C. Storm, Ryan J. Law, Eric J. Vargas, Vishal Garimella, Tyler Zemla, Sarah M. Jenkins, Jun Yin, Gregory J. Gores, Lewis R. Roberts, Benjamin R. Kipp, Vinay Chandrasekhara
Background and Aims: Early identification of malignant biliary strictures (MBS) is challenging, with up to 20% classified as indeterminants after preliminary testing and tissue sampling with endoscopic retrograde cholangiopancreatography (ERCP). We aimed to evaluate the use of methylated DNA markers (MDM) from biliary brushings to enhance MBS detection in a prospective cohort. Methods: Candidate MDMs
-
Letter to the Editor: MAFLD versus MASLD criteria debate- Certainly not for children! Hepatology (IF 12.9) Pub Date : 2024-06-20 Mortada H. F. El-Shabrawi, Abdelaziz Elamin, Naglaa M. Kamal
-
Spatial proteomic landscape of primary and relapsed hepatocellular carcinoma reveals immune escape characteristics in early relapse Hepatology (IF 12.9) Pub Date : 2024-06-20 Meilin Yang, Xiaoyi Song, Fan Zhang, Mingan Li, Wuguang Chang, Zheyan Wang, Man Li, Hong Shan, Dan Li
Background & Aims: Surgical resection serves as the principal curative strategy for hepatocellular carcinoma (HCC), yet the incidence of postoperative recurrence remains alarmingly high. However, the spatial molecular structural alterations contributing to postoperative recurrence in HCC are still poorly understood. Approach & Results: We employed imaging mass cytometry to profile the in-situ expression
-
Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis Hepatology (IF 12.9) Pub Date : 2024-06-20 Juan Berenguer, José M. Bellón, Rafael Bañares, Juan González-García
-
Genetic predisposition to porto-sinusoidal vascular disorder Hepatology (IF 12.9) Pub Date : 2024-06-20 Nadia Ciriaci, Lise Bertin, Pierre-Emmanuel Rautou
Porto-sinusoidal vascular disorder is a rare liver disease. The pathophysiological mechanisms underlying the development of porto-sinusoidal vascular disorder are unknown. Isolated cases of porto-sinusoidal vascular disorder associated with gene mutations have been reported, but no overview is available. Therefore, we performed an extensive literature search to provide a comprehensive overview of gene
-
Digestive Disease Week 2024 Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-06-17 Katrina Ray
From 18–21 May 2024, Nature Reviews Gastroenterology & Hepatology was back at Digestive Disease Week (DDW) in Washington DC, USA, alongside >14,300 attendees both in person and virtually, according to the organizers. A wide array of sessions were available, covering basic, translational and clinical science in gastroenterology and hepatology. For basic and translational sciences, talks on the gut microbiome
-
Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide. J. Hepatol. (IF 26.8) Pub Date : 2024-06-18 Pierluigi Toniutto, Edmondo Falleti, Sara Cmet, Annarosa Cussigh, Elisabetta Degasperi, Maria Paola Anolli, Dana Sambarino, Floriana Facchetti, Marta Borghi, Riccardo Perbellini, Sara Monico, Pietro Lampertico
-
Reply to: “Mycophenolate mofetil in autoimmune hepatitis: Are we ready for primetime?” J. Hepatol. (IF 26.8) Pub Date : 2024-06-15 Charlotte D. Slooter, Anna E.C. Stoelinga, Romée J.A.L.M. Snijders
-
Intermittent fasting for NASH and HCC in mice Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-06-14 Jordan Hindson
A recent study published in Cell Metabolism has investigated the effect of intermittent fasting on nonalcoholic steatohepatitis (NASH) and NASH-related hepatocellular carcinoma (HCC) in mice. First, the researchers demonstrated that Western diet-fed mice put on an intermittent fasting regimen (consisting of 2 non-consecutive days of fasting per week) were resistant to obesity and had significantly
-
Next generation of gastrointestinal electrophysiology devices Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-06-14 Haitao Liu, Siheng Sean You, Zhigang Gao, Ning Hu, Yunlong Zhao
-
Unlocking the promise of RAS inhibition in pancreatic cancer Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-06-14 Saurav D. Haldar, Nilofer S. Azad
-
Real-world evidence for factors associated with maintenance treatment practices among U.S. adults with autoimmune hepatitis Hepatology (IF 12.9) Pub Date : 2024-06-12 Therese Bittermann, Lina Yagan, Ranganath G. Kathawate, Ethan M. Weinberg, Eliot G. Peyster, James D. Lewis, Cynthia Levy, David S. Goldberg
Background & Aims: While avoidance of long-term corticosteroids is a common objective in the management of autoimmune hepatitis (AIH), prolonged immunosuppression is usually required to prevent disease progression. This study investigates the patient and provider factors associated with treatment patterns in U.S. patients with AIH. Approach & Results: A retrospective cohort of adults with incident
-
Perianal fistulizing Crohn’s disease-associated anorectal and fistula cancers: systematic review and expert consensus Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-06-12 Serre-Yu Wong, Cathy Rowan, Elvira Diaz Brockmans, Cindy CY. Law, Elisabeth Giselbrecht, Celina Ang, Sergey Khaitov, David Sachar, Alexandros D. Polydorides, Leon Shin-han Winata, Bram Verstockt, Antonino Spinelli, David T. Rubin, Parakkal Deepak, Dermot P.B. McGovern, Benjamin D. McDonald, Phillip Lung, Lilli Lundby, Amy L. Lightner, Stefan D. Holubar, Luke Hanna, Carla Hamarth, Jeroen Geldof, Anders
Perianal fistulizing Crohn’s disease (PFCD)-associated anorectal and fistula cancers are rare but often devastating diagnoses. However, given the low incidence and consequent lack of data and clinical trials in the field, there is little to no guidance on screening and management of these cancers. To inform clinical practice, we developed consensus guidelines on PFCD-associated anorectal and fistula
-
Reply to: “Evidence and choice: The BCLC vision for tailoring clinical decision-making” J. Hepatol. (IF 26.8) Pub Date : 2024-06-11 Franco Trevisani, Alessandro Vitale, Agostino Colli, Masatoshi Kudo, Laura Kulik, Joon-Won Park, David J. Pinato, Umberto Cillo
-
Reply to: ‘Exploring hepatocellular carcinoma risks in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe’ J. Hepatol. (IF 26.8) Pub Date : 2024-06-11 Lesley A. Patmore, Milan J. Sonneveld
-
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases Hepatology (IF 12.9) Pub Date : 2024-06-11 Shouzhi Yang, Jing Fu, Wenhao Qin, Ruimin Wang, Mingye Gu, Yida Huang, Wanshan Liu, Haiyang Su, Xiaoyu Xu, Wei Chen, Ayizekeranmu Yiming, Bing Hu, Lin Huang, Kun Qian, Hongyang Wang
Background and Aims: Biliary tract cancers (BTCs) are aggressive gastrointestinal malignancies characterized by a dismal 5-year overall survival rate less than 20%. Current diagnostic modalities suffer from limitations regarding sensitivity and specificity. This study aimed to develop a bile metabolite-based platform for precise discrimination between malignant and benign biliary diseases. Approach
-
REPLY: The exact predictive value of HBcrAg and HBV RNA in serological status and disease activity in CHB Hepatology (IF 12.9) Pub Date : 2024-06-11 Marc G. Ghany, Wendy C. King, Amanda S. Hinerman, Anna S.F. Lok, Mauricio Lisker-Melman, Raymond T. Chung, Norah Terrault, Harry L.A. Janssen, Mandana Khalili, William M. Lee, Daryl T.Y. Lau, Gavin A. Cloherty, Richard K. Sterling
-
Screening Endoscopy in Patients With Advanced Chronic Liver Disease – Is It All About Varices? Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-06-11 Rui Morais, Rodrigo Liberal, Guilherme Macedo
-
Screening for Social Determinants of Health in Underserved Populations to Promote Better Outcomes in ALD and MASLD Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-06-11 Michael Sun, Aivi A. Rahman, Vincent J.H. Yao
-
Reply to: “Non-acute decompensation cannot be ignored in future research and clinical practice” J. Hepatol. (IF 26.8) Pub Date : 2024-06-10 Marta Tonon, Anna Barone, Valeria Calvino, Valeria Santori, Paolo Angeli
-
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Eric J. Lawitz, Mandy Fraessdorf, Guy W. Neff, Jörn M. Schattenberg, Mazen Noureddin, Naim Alkhouri, Bernhard Schmid, Charles P. Andrews, István Takács, Samina Ajaz Hussain, Wiebke K. Fenske, Edward J. Gane, Azadeh Hosseini-Tabatabaei, Arun J. Sanyal, Daniel F. Mazo, Ramy Younes, for the NCT05296733 Investigators
-
THU-375 When glecaprevir/pibrentasvir ultra-short therapy is enough to eradicate HCV infection J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Alberto Grassi, Natascia Celli, Silvana Maccariello, Gabriele Donati, Angela Fabbri, Giorgio Ballardini
-
THU-374 Description of age, sex, and characteristics of hepatitis C patients in the SVR10 K study: a real-world SOF/VEL analysis performed across five global regions J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Soo Aleman, Fatima Higuera-de-la-Tijera, Francisco Javier Garcia-Samaniego, Marta Casado-Martin, Grace Lai-Hung Wong, Mohammed Alzaabi, Habiba Kamal, Karin Lindahl, Aastha Chandak, Marta Martinez, Artak Khachatryan, Linda Chen, Candido Hernández, Kim Vanstraelen, Ming-Lung Yu
-
THU-373-YI Quality of etiotropic therapy efficasy of chronic hepatitis C patients in accordance of toll-like receceptor 4 +3725G/C gene polymorfisms variety J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Tetiana Bevz, Larysa Moroz, Kiarina Myroniuk-Konstantynovych, Iryna Bondaruk, Galyna Martyniuk, Yaroslav Demchyshyn
-
THU-372-YI Point of care hepatitis C screening and treatment among people who use drugs in new york city addiction centers: barriers and opportunities J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Jessica Siguencia, Jhané Phanor, Anthony Choi, Robert S. Brown Jr, Laura Maroldo
-
THU-371 Impact of a simplified diagnosis-monitoring strategy on Glecaprevir/Pibrentasvir (G/P) treatment initiation and response in patients with chronic hepatitis C virus (HCV) infection receiving opioid substitute therapy in Israel-a real world evidence J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Eli Zuckerman, Orly Azulay
-
THU-370 Hepatocellular carcinoma may be a viral reservoir during treatment of hepatitis C with direct-acting antivirals J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Mário Jorge Silva, Ana Patricia Negrinho, Fatima Oliveira Martins, Antonio Figueiredo, Helena Gloria, Carina Santos, Pedro Lages Martins, Vasco Ribeiro, Mario Oliveira, Hugo Pinto Marques, Silvia Vilares Conde, Filipe Calinas
-
THU-367-YI Effectiveness and safety of direct-acting antivirals in the treatment of elderly people infected with HCV J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Michał Brzdęk, Dorota Zarębska-Michaluk, Krzysztof Tomasiewicz, Magdalena Tudrujek-Zdunek, Beata Lorenc, Włodzimierz Mazur, Hanna Berak, Justyna Janocha-Litwin, Jakub Klapaczynski, Ewa Janczewska, Dorota Dybowska, Anna Parfieniuk-Kowerda, Piekarska Anna, Jerzy Jaroszewicz, Robert Flisiak
-
THU-366 Use of proton pump inhibitors among German Hepatitis C patients treated with sofosbuvir/velpatasvir: Data from the German Hepatitis C-Registry (2016–2022) J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Markus Cornberg, Gerlinde Teuber, Ralf Link, Uwe Naumann, Hartwig Klinker, Christine John, Candido Hernández, Marianna Schwenken, Christoph Sarrazin
-
THU-365 Real-world effectiveness and safety of 8-week glecaprevir/ pibrentasvir for treatment-naïve patients from Taiwan nationwide HCV registry J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Chung-Feng Huang, Te-Sheng Chang, Hsing-Tao Kuo, Chien-Wei Huang, Lien-Ray Mo, Chi-Ming Tai, Kuo-Chih Tseng, Ming-Jong Bair, Sih-Ren Wang, Ching-Chu Lo, Lee-Won Chong, Pin-Nan Cheng, Ming-Lun Yeh, Cheng-Yuan Peng, Chien-Yu Cheng, Jee-Fu Huang, Chih-Lang Lin, Chi-Chieh Yang, Tsai-Yuan Hsieh, Tzong-Hsi Lee, Pei-Lun Lee, Wen-Chih Wu, Chih-Lin Lin, Wei-Wen Su, Sheng-Shun Yang, Chia-Chi Wang, Jui-Ting Hu
-
THU-364 Modeling suggests that undetectable HCV at week 2 of DAA therapy could identify patients for shorter treatment duration J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Ashish Goyal, Ohad Etzion, Kimberly Page, Tatyana Kushner, Yedidya Saiman, Scott Cotler, Harel Dahari
-
THU-363 Validation of a modified pediatric formulation of Sofosbuvir and Daclatasvir in genotype-4 HCV-infected children weighing 17– 35 Kg J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Ahmed Farrag, Maggie Abbassi, Fatma Ebeid, Tim Cressey, Philippa Easterbrook, Nirmeen Sabry, Manal El-Sayed
-
THU-362 Ravidasvir in combination with sofosbuvir for 12 or 24 weeks achieved high sustained virological response rates in genotype 3 chronic hepatitis C without or with compensated liver cirrhosis J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Soek Siam Tan, Caroline Menétrey, Isabela Ribeiro, Nicolas Salvadori, Sabine Yerly, Nicole Ngo-Giang-Huong, Graciela Diap
-
THU-420 Evaluation of LiverRisk score as predictor of liver fibrosis and mortality in patients with HCV-related hepatitis treated with direct acting antivirals J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Antonietta Romano, Amalia Rita Caspanello, Salvatore Piano, Marta Tonon, Carmine Gambino, Valeria Calvino, Anna Barone, Nicola Zeni, Simone Incicco, Roberta Gagliardi, Paolo Angeli
-
THU-419 Regression of hepatic fibrosis in patients with chronic hepatitis C treated with direct-acting antivirals (DAAs). A long-term, prospective, observational study J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Evdoxia Avramopoulou, Efthymios Tsounis, Stavros Kanaloupitis, Konstanitnos Zisimopoulos, Maria Kalafateli, Ioanna Aggeletopoulou, Christos Sotiropoulos, Theodora Kafentzi, Georgios Geramoutsos, Odysseas Ampazis, Georgia Diamantopoulou, Angeliki Tsintoni, Konstantinos Thomopoulos, Christos Triantos
-
THU-418 Screening for chronic hepatitis C in pre-surgical patients J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Mercedes Vergara, Gemma Solé, Isabel Esteve, Meritxell Casas, Jordi Sánchez, Cristina Solé, José Alberto Ferrusquía, Mireia Miquel
-
THU-414 Incidence of hepatocellular carcinoma in patients with hepatitis C treated with direct-acting antivirals agents: results of a long-term prospective study period J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Emanuela De Santis, Alessandro Caioli, Fernando De Angelis, Adriano De Santis
-
THU-413 Baseline gamma-glutamyl transpeptidase levels are associated with aggravation of esophagogastric varix after direct-acting antiviral therapy in cirrhotic patients with hepatitis C virus J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Yuki Tahata, Hayato Hikita, Satoshi Mochida, Akio Ido, Daiki Miki, Ryotaro Sakamori, Hitoshi Yoshiji, Norifumi Kawada, Nobuyuki Enomoto, Taro Yamashita, Masayuki Kurosaki, Hidekatsu Kuroda, Yoichi Hiasa, Kazuhiko Nakao, Naoya Kato, Goki Suda, Yasunari Nakamoto, Hiroshi Yatsuhashi, Kentaro Matsuura, Taro Takami, Eiji Kakazu, Yoshito Itoh, Yasuhiro Asahina, Yoshiyuki Ueno, Ryosuke Tateishi, Shuji Terai
-
THU-412 Hepatitis C lost to follow-up rates in primary care practices in Belgium J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Marie Coessens, Jeoffrey Schouten, Wim Verlinden
-
THU-411 Long term liver-related events in patients with HCV-related liver disease and advanced fibrosis after sustained virological response with direct-acting antivirals J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Jorge Barajas, Tomás Artaza, JuanJosé Sánchez-Ruano, Marta Romero-Gutiérrez, Carolina Delgado, Gema De la Cruz, Concepción Gonzalez, Raquel Lomas, Rafael Gómez Rodríguez
-
THU-410 Clinical interventions and use of resources for the management of adverse effects associated with multiple drug interactions in the hepatitis C population J. Hepatol. (IF 26.8) Pub Date : 2024-06-08 Juan Turnes, Antonio Garcia Herola, Ramón Morillo Verdugo, Marinela Mendez, Candido Hernández, Antoni Sicras Mainar